Byrna Technologies Sets Upcoming Investor Conference Schedule
Get Alerts BYRN Hot Sheet
Join SI Premium – FREE
ANDOVER, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, is scheduled to participate at the following upcoming financial conferences.
B. Riley Securities 2026 Investor Conference
Date: May 20, 2026
Location: Ritz-Carlton, Marina Del Rey (Marina Del Rey, California)
Format: One-on-one and small group meetings
Craig-Hallum 23rd Annual Institutional Investor Conference
Date: May 28, 2026
Location: Renaissance Minneapolis Hotel, The Depot (Minneapolis, MN)
Format: One-on-one and small group meetings
For additional information or to schedule a one-on-one meeting with Byrna’s management team, please contact Gateway Group at [email protected].
About Byrna Technologies Inc.
Byrna is a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions. For more information on the Company, please visit the corporate website here or the Company’s investor relations site here. The Company is the manufacturer of the Byrna® CL, Byrna® LE and Byrna® SD personal security devices, state-of-the-art handheld CO2 powered launchers designed to provide a less-lethal alternative to a firearm for the consumer, private security, and law enforcement markets. To purchase Byrna products, visit the Company’s e-commerce store.
Investor Contact:
Tom Colton and Alec Wilson
Gateway Group, Inc.
949-574-3860
[email protected]
Source: Byrna Technologies, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
- Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
- Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
B. RileySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share